Day: September 28, 2022

WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session at the upcoming 2022 American Heart Association (AHA) Scientific Sessions taking place November 5-7, 2022, virtually and in Chicago, Illinois. Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase. The presentation will include clinical data from CinCor’s BrigHtn trial, a Phase 2 randomized, double-blind, multicenter, placebo-controlled dose-ranging study designed to assess the safety and efficacy of baxdrostat in subjects who have not achieved their target blood pressure despite receiving three or more...

Exela will provide technology and operation solutions in total contract value of ~$8 million Exela’s PCH Global Cloud Platform continues to connect members in multiple healthcare organizations, health insurers and US government programsIRVING, Texas, Sept. 28, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or “the Company”) (NASDAQ: XELA, XELAP), today announced an expanded strategic partnership to utilize Exela’s technology and operations solutions valued at total contract value of ~$8 million. The win is part of the Healthcare Solutions business which generated $218 million in revenue in 2021. The company’s solution utilizes PCH Global to enhance consumer engagement, drive preventative care and improve the health care user experience. Exela continues to be on the forefront of healthcare technology including advances...

      NFI’s long-range, sustainable, and smart city-capable coach delivers excellent performance through high-power batteries, interoperable plug-in charging, and a high-torque electric drive system https://www.youtube.com/watch?v=9GecfRe_IoU DES PLAINES, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that its subsidiary Motor Coach Industries (“MCI”) has unveiled its new zero-emission, battery-electric high-floor commuter coach – the D45 CRT CHARGE™. The D45 CRT CHARGE™ – a zero-emission version of the best-selling D45 Commuter Rapid Transit (“CRT”) series public transit coach – integrates proven CHARGE propulsion from New Flyer, including regenerative...

FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in translational science and clinical research that will help guide the Company’s research and development strategy.  “As the evidence supporting the therapeutic potential of our pipeline products continues to grow, we are very pleased to collaborate with leading experts that can help us inform key decisions pertaining to our drug development strategy”, said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur continued, “With access to the vast knowledge...

LONDON, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) — Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced it will be presenting at the upcoming Roth Inaugural Healthcare Opportunities Conference being held in-person in New York, NY on October 6, 2022. Company management will also be participating in one-on-one investor meetings at the conference. Roth Inaugural Healthcare Opportunities ConferenceDate: Thursday, October 6, 2022Presenter: Dr. Philip Toleikis, President & CEO, Sernova CorpLocation: The Yale Club, New York, NYPlease contact your Roth representative to schedule one-on-one meetings with the management team during the conference. ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY Sernova Corp. is...

TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a multi-year licensing contract of subsidiary Transforming System’s SHREWD Platform and SHREWD Resilience offerings to NHS Mid and South Essex Integrated Care Board (“Essex”). NHS Mid and South Essex Integrated Care Board serves a population in excess of 1.2 million people, and spans the following care organizations: Mid and South Essex NHS Foundation Trust, Essex Partnership University NHS Foundation Trust, North East London NHS Foundation Trust, East of England Ambulance Service NHS Foundation Trust, Essex County Council, Southend-on-Sea City Council, and Thurrock Council. This represents a new customer contract that will afford Essex with visibility into the entire health system in real time, enabling improved...

Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023 GAITHERSBURG, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of first dosing of all subjects in its Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). MOMENTUM is a multicenter, randomized, placebo-controlled trial that is ongoing at approximately 30 sites in the United States, with Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity...

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11th, 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach. “We initiated this program in 2018 with the goal of helping patient advocacy organizations advance often under-funded marketing and communications efforts,”...